In vitro susceptibility of eighteen clinical isolates of human monkeypox virus to tecovirimat.

ABSTRACT:

Background

In 2022, an outbreak of mpox that started in European countries spread worldwide through human-to-human transmission. Cases have been mostly mild, but severe clinical presentations have been reported. In these cases, tecovirimat has been the drug of choice to treat patients with aggravated disease.

Objectives

Here we investigated the tecovirimat susceptibility of 18 clinical isolates of monkeypox virus (MPXV) obtained from different regions of Brazil.

Methods

Different concentrations of tecovirimat were added to cell monolayers infected with each MPXV isolate. After 72 hours, cells were fixed and stained for plaque visualization, counting, and measurement. The ortholog of F13L gene from each MPXV isolate was polymerase chain reaction (PCR)-amplified, sequen

SUBMITTER: Nunes DDS 

PROVIDER: S-EPMC10337824 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature